Vasoactive prostaglandins in the impending no-reflow state: evidence for a primary disturbance in microvascular tone - PubMed (original) (raw)
Vasoactive prostaglandins in the impending no-reflow state: evidence for a primary disturbance in microvascular tone
L J Feng et al. Plast Reconstr Surg. 1988 May.
Abstract
The impending no-reflow (NRF) state was studied in the rat hindlimb to identify possible biochemical mediators producing the no-reflow phenomenon. After 5 hours of ischemia, the venous effluents draining the ischemic limb and the contralateral nonischemic limb were collected for three 30-minute time periods. Thromboxane B2 (TxB2), prostaglandin E2 (PGE2), and 6-ketoprostaglandin F1 alpha, the stable metabolite of prostacyclin (PGI2), were measured by radioimmunoassay. Venous outflow rate, distal skin perfusion assessed by dermofluorometry, and histology of muscle and skin were examined in control limbs, ischemic limbs, and limbs with impending no reflow. The no-reflow state was characterized by a significantly decreased venous outflow (less than 0.01 ml per minute), decreased skin perfusion (index of fluorescence of 15 percent in no-reflow limbs versus 70 percent in reflow limbs), and absence of thrombosis of the vasculature. The no-reflow state also was associated with 2.4 times more thromboxane B2 and 1.5 times more 6-ketoprostaglandin F1 alpha than that observed in ischemic limbs with reflow. The biosynthesis of vasodilating prostaglandin E2 in the no-reflow state, however, was only 40 percent of the prostaglandin E2 measured in limbs with reflow. We propose that the impending no-reflow state may reflect a state of global microcirculatory "agonal" vasoconstriction, most probably due to an overabundant release of the vasoconstrictor thromboxane relative to the vasodilating prostaglandin E2 and prostacyclin. The likelihood of specific biochemical mechanisms producing the no-reflow state suggests that pharmacologic agents may be able to reverse the impending no-reflow state to improve tissue survival.
Similar articles
- 6-Ketoprostaglandin F1 alpha, prostaglandins E2, F2 alpha and thromboxane B2 production by endothelial cells, smooth muscle cells and fibroblasts cultured from piglet aorta.
Ody C, Seillan C, Russo-Marie F. Ody C, et al. Biochim Biophys Acta. 1982 Jul 20;712(1):103-10. doi: 10.1016/0005-2760(82)90090-x. Biochim Biophys Acta. 1982. PMID: 6214281 - Vasodilating prostaglandins attenuate ischemic renal injury only if thromboxane is inhibited.
Klausner JM, Paterson IS, Kobzik L, Rodzen C, Valeri CR, Shepro D, Hechtman HB. Klausner JM, et al. Ann Surg. 1989 Feb;209(2):219-24. doi: 10.1097/00000658-198902000-00013. Ann Surg. 1989. PMID: 2644899 Free PMC article. - Studies on the control of prostaglandin production by the hypothalamus in relation to LH release in the rat.
Brown CG, Poyser NL. Brown CG, et al. J Endocrinol. 1984 Nov;103(2):155-64. doi: 10.1677/joe.0.1030155. J Endocrinol. 1984. PMID: 6593408 - Effect of cyclosporine on glomerular prostaglandin production.
Bunke M, Wilder L, McLeish K. Bunke M, et al. Transplant Proc. 1988 Jun;20(3 Suppl 3):646-9. Transplant Proc. 1988. PMID: 3164533 No abstract available. - Effect of dexamethasone on prostaglandin synthesis in various areas of the rat brain.
Weidenfeld J, Lysy J, Shohami E. Weidenfeld J, et al. J Neurochem. 1987 May;48(5):1351-4. doi: 10.1111/j.1471-4159.1987.tb05670.x. J Neurochem. 1987. PMID: 3470438
Cited by
- Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms.
Francis A, Baynosa R. Francis A, et al. Diving Hyperb Med. 2017 Jun;47(2):110-117. doi: 10.28920/dhm47.2.110-117. Diving Hyperb Med. 2017. PMID: 28641323 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources